The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Continuous fluropyrimidine (FP) with platinum (P) based chemotherapy (CT) versus maintenance FP after induction therapy in advanced gastric (G) and gastroesophageal (GE) cancer.
 
Daniel Walden
No Relationships to Disclose
 
Mohamad Bassam Sonbol
No Relationships to Disclose
 
Skye Buckner Petty
No Relationships to Disclose
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; AVEO; AVEO; AVEO; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Inspyr Therapeutics; Inspyr Therapeutics; Inspyr Therapeutics; Inspyr Therapeutics; Insys Therapeutics (Inst); Insys Therapeutics (Inst); Insys Therapeutics (Inst); Insys Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TD2; TD2; TD2; TD2
Research Funding - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); ARIAD (Inst); ARIAD (Inst); ARIAD (Inst); ARIAD (Inst); BiolineRx (Inst); BiolineRx (Inst); BiolineRx (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Dicerna (Inst); Dicerna (Inst); Dicerna (Inst); Dicerna (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); ImClone Systems (Inst); ImClone Systems (Inst); ImClone Systems (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); Isis Pharmaceuticals (Inst); Isis Pharmaceuticals (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); miRNA Therapeutics (Inst); miRNA Therapeutics (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Threshold Pharmaceuticals (Inst); Threshold Pharmaceuticals (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst); Toray Industries (Inst); Toray Industries (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; ArQule; ArQule; ArQule; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Celgene; Celgene; Celgene; Celgene
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Amgen; Amgen; Amgen; Amgen; Amgen (Inst); Amgen (Inst); AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Immuneering; Immuneering; Immuneering; Immuneering; Imugene; Imugene; Imugene; Imugene; Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly; Lilly; Lilly; Lilly; Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); NCCN; NCCN; NCCN; NCCN; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Regeneron; Regeneron; Regeneron; Regeneron; Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - NCCN; NCCN; NCCN; NCCN; NCI; NCI; NCI; NCI; Oncolytics; Oncolytics; Oncolytics; Oncolytics
Other Relationship - ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Exelixis; Exelixis; Exelixis; Exelixis; Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Polaris; Polaris; Polaris; Polaris; Sillajen; Sillajen; Sillajen; Sillajen
 
Daniel H. Ahn
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Cardinal Health; Cardinal Health; Cardinal Health; Cardinal Health; Celltrion (I); Celltrion (I); Celltrion (I); Celltrion (I); Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Lexicon; Lexicon; Lexicon; Lexicon